Changes in endocannabinoid and N-acylethanolamine levels in rat brain structures following cocaine self-administration and extinction training

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 50, Issue , 2014, Pages 1-10

  Bystrowska, Beata ^a   Smaga, Irena ^a   Frankowska, Małgorzata ^b   Filip, Małgorzata ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

"Yoked" procedure; Cocaine self administration; Endocannabinoid; N acylethanolamine

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; COCAINE; ENDOCANNABINOID; ETHANOLAMINE DERIVATIVE; N ACYLETHANOLAMINE; N OLEOYLETHANOLAMINE; PALMIDROL; UNCLASSIFIED DRUG; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; AMIDE; ARACHIDONIC ACID DERIVATIVE; N-ACYLETHANOLAMINES; OLEIC ACID; PALMITIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG SELF ADMINISTRATION; FRONTAL CORTEX; HIPPOCAMPUS; LIMBIC CORTEX; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEUS ACCUMBENS; RAT; REINFORCEMENT; SUBCORTEX; TISSUE LEVEL; ANIMAL; BRAIN; DRUG EFFECTS; INSTRUMENTAL CONDITIONING; METABOLISM;

ANIMALS; ARACHIDONIC ACIDS; BRAIN; COCAINE; CONDITIONING, OPERANT; ENDOCANNABINOIDS; ETHANOLAMINES; EXTINCTION, PSYCHOLOGICAL; GLYCERIDES; MALE; OLEIC ACIDS; PALMITIC ACIDS; POLYUNSATURATED ALKAMIDES; RATS; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION;

EID: 84890890853     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.12.002     Document Type: Article

References (89)

1. Adamczyk P., McCreary A.C., Przegalinski E., Mierzejewski P., Bienkowski P., Filip M. The effects of fatty acid amide hydrolase inhibitors on maintenance of cocaine and food self-administration and on reinstatement of cocaine-seeking and food-taking behavior in rats. J Physiol Pharmacol 2009, 60:119-125.
2. 3H]CP55,940 binding to CB1 receptors following cocaine self-administration and its withdrawal in rats. Brain Res 2012, 1451:34-43.
3. Adamczyk P., Miszkiel J., McCreary A.C., Filip M., Papp M., Przegaliński E. The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats. Brain Res 2012, 1444:45-54.
4. Arnold J.C. The role of endocannabinoid transmission in cocaine addiction. Pharmacol Biochem Behav 2005, 81:396-406.
5. Barrantes F.J. Structural basis for lipid modulation of nicotinic acetylcholine receptor function. Brain Res Brain Res Rev 2004, 47:71-95.
6. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997, 277:1094-1097.
7. Bilbao A., Blanco E., Luque-Rojas M.J., Suárez J., Palomino A., Vida M., et al. Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARα receptor-independent mechanism. Addict Biol 2013, 18:78-87.
8. Bossert J.B., Ghitza U.E., Lu L., Epstein D.H., Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol 2005, 526:36-50.
9. Buczynski M., Polis I., Parsons L. The volitional nature of nicotine exposure alters anandamide and oleoylethanolamide levels in the ventral tegmental area. Neuropsychopharmacology 2013, 38:574-584.
10. Budzyńska B., Kruk M., Biała G. Effects of the cannabinoid CB1 receptor antagonist AM 251 on the reinstatement of nicotine-conditioned place preference by drug priming in rats. Pharmacol Rep 2009, 61:304-310.
11. Butt C.M., Hutton S.R., Marks M.J., Collins A.C. Bovine serum albumin enhances nicotinic acetylcholine receptor function in mouse thalamic synaptosomes. J Neurochem 2002, 83:48-56.
12. Caillé S., Alvarez-Jaimes L., Polis I., Stouffer D., Parsons L. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci 2007, 27:3695-3702.
13. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394:277-281.
14. Centonze D., Battista N., Rossi S., Mercuri N.B., Finazzi-Agrò A., Bernardi G., et al. A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal GABAergic transmission. Neuropsychopharmacology 2004, 29:1488-1497.
15. Cimini A., Benedetti E., Cristiano L., Sebastiani P., D'Amico M.A., D'Angelo B., et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 2005, 130:325-337.
16. Cravatt B.F., Lichtman A.H. The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids 2002, 121:135-148.
17. De Vries T.J., Shaham Y., Homberg J.R., Crombag H., Schuurman K., Dieben J., et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 2001, 7:1151-1154.
18. Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 1995, 38:95-137.
19. Di Marzo V. Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nat Neurosci 2011, 14:9-15.
20. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372:686-691.
21. Di Marzo V., Melck D., Orlando P., Bisogno T., Zagoory O., Bifulco M., et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 2001, 358:249-255.
22. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 2005, 313:352-358.
23. +-evoked [3H]-dopamine efflux from rat striatal synaptosomes: a novel action of cocaine. J Neural Transm 2010, 117:593-597.
24. Ferraro L., Frankowska M., Marcellino D., Zaniewska M., Beggiato S., Filip M., et al. A novel mechanism of cocaine to enhance dopamine d2-like receptor mediated neurochemical and behavioral effects. An in vivo and in vitro study. Neuropsychopharmacology 2012, 37:1856-1866.
25. Filip M. Role of serotonin (5-HT)2 receptors in cocaine self-administration and seeking behavior in rats. Pharmacol Rep 2005, 57:35-46.
26. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957, 226:497-509.
27. Frankowska M., Wydra K., Faron-Górecka A., Zaniewska M., Kuśmider M., Dziedzicka-Wasylewska M., et al. Neuroadaptive changes in the rat brain GABA B receptors after withdrawal from cocaine self-administration. Eur J Pharmacol 2008, 599:58-64.
28. Frankowska M., Gołda A., Wydra K., Gruca P., Papp M., Filip M. Effects of imipramine or GABA B receptor ligands on the immobility, swimming and climbing in the forced swim test in rats following discontinuation of cocaine self-administration. Eur J Pharmacol 2010, 627:142-149.
29. Fu J., Gaetani S., Oveisi F., Lo Verme J., Serreno A., Rodríguez De Fonseca F., et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003, 425:90-93.
30. Fu J., Kim J., Oveisi F., Astarita G., Piomelli D. Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. Am J Physiol Regul Integr Comp Physiol 2008, 295:45-50.
31. Fuchs R.A., Eaddy J.L., Su Z., Bell G.H. Interactions of the basolateral amygdala with the dorsal hippocampus and dorsomedial prefrontal cortex regulate drug context-induced reinstatement of cocaine-seeking in rats. Eur J Neurosci 2007, 26:487-498.
32. Gass J.T., Chandler L.J. The plasticity of extinction: contribution of the prefrontal cortex in treating addiction through inhibitory learning. Front Psychiatry 2013, 4(46):1-13.
33. Genedani S., Carone C., Guidolin D., Filaferro M., Marcellino D., Fuxe K., et al. Differential sensitivity of A2A and especially D2 receptor trafficking to cocaine compared with lipid rafts in cotransfected CHO cell lines. Novel actions of cocaine independent of the DA transporter. J Mol Neurosci 2010, 41:347-357.
34. Gerdeman G.L., Schechter J.B., French E.D. Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant. Neuropsychopharmacology 2008, 33:2747-2759.
35. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999, 2:358-363.
36. Giuffrida A., Rodríguez de Fonseca F., Piomelli D. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal Biochem 2000, 280:87-93.
37. Gonzalez S., Cascio M., Fernandez-Ruiz J., Fezza F., Di Marzo V., Ramos J.A. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 2002, 954:73-81.
38. 9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. Drug Alcohol Depend 2004, 74:159-170.
39. Hansen H.S. Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol 2010, 224:48-55.
40. Hansen H.S., Diep T.A. N-acylethanolamines, anandamide and food intake. Biochem Pharmacol 2009, 78:553-560.
41. Hill M., McLaughlin R., Bingham B., Shrestha L., Lee T., Gray M., et al. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci U S A 2010, 18(107):9406-9411.
42. Hill M., Patel S., Campolongo P., Tasker J., Wotjak C., Bains J. Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci 2010, 30:14980-14986.
43. Hnasko T.S., Sotak B.N., Palmiter R.D. Cocaine-conditioned place preference by dopamine-deficient mice is mediated by serotonin. J Neurosci 2007, 27:12484-12488.
44. Jaggar S.I., Hasnie F.S., Sellaturay S., Rice A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998, 76:189-199.
45. Jonsson K.O., Vandevoorde S., Lambert D.M., Tiger G., Fowler C.J. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol 2001, 133:1263-1275.
46. Justinova Z., Mangieri R.A., Bortolato M., Chefer S.I., Mukhin A.G., Clapper J.R., et al. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 2008, 64:930-937.
47. Justinova Z., Munzar P., Panlilio L.V., Yasar S., Redhi G.H., Tanda G., et al. Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacology 2008, 33:2870-2877.
48. Kalivas P.W., McFarland K. Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology 2003, 168:44-56.
49. Kozak K.R., Crews B.C., Morrow J.D., Wang L.H., Ma Y.H., Weinander R. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 2002, 277:44877-44885.
50. Kreek M.J., Levran O., Reed B., Schlussman S.D., Zhou Y., Butelman E.R. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J Clin Invest 2012, 122:3387-3393.
51. Kurtuncu M., Battista N., Uz T., D'Agostino A., Dimitrijevic N., Pasquariello N., et al. Effects of cocaine in 5-lipoxygenase-deficient mice. J Neural Transm 2008, 115:389-395.
52. Lafourcade M., Elezgarai I., Mato S., Bakiri Y., Grandes P., Manzoni O.J. Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One 2007, 2:e709.
53. Lesscher H., Hoogveld E., Burbach J.P., van Ree J., Gerrits M. Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. Eur Neuropsychopharmacol 2005, 15:31-37.
54. Li X., Hoffman A.F., Peng X.Q., Lupica C.R., Gardner E.L., Xi Z.X. Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology (Berl) 2009, 204:1-11.
55. Luque-Rojas M.J., Galeano P., Suárez J., Araos P., Santín L.J., de Fonseca F.R., et al. Hyperactivity induced by the dopamine D2/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice. Int J Neuropsychopharmacol 2013, 16:661-676.
56. Maccarrone M., Rossi S., Bari M., De Chiara V., Fezza F., Musella A., et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 2008, 11:152-159.
57. Mascia P., Pistis M., Justinova Z., Panlilio L.V., Luchicchi A., Lecca S., et al. Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 2011, 69:633-641.
58. Mazzola C., Medalie J., Scherma M., Panlilio L.V., Solinas M., Tanda G., et al. Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn Mem 2009, 16:332-337.
59. Melis M., Pillolla G., Luchicchi A., Muntoni A.L., Yasar S., Goldberg S.R., et al. Endogenous fatty acid ethanolamides suppress -induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci 2008, 28:13985-13994.
60. Miquel M., Toledo R., García L., Coria-Avila G., Manzo J. Why should we keep the cerebellum in mind when thinking about addiction?. Curr Drug Abuse Rev 2009, 2:26-40.
61. Moreno S., Farioli-Vecchioli S., Cerù M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004, 123:131-145.
62. Mulder A.M., Cravatt B.F. Endocannabinoid metabolism in the absence of fatty acid amide hydrolase (FAAH): discovery of phosphorylcholine derivatives of N-acyl ethanolamines. Biochemistry 2006, 45:11267-11277.
63. Murillo-Rodríguez E., Palomero-Rivero M., Millán-Aldaco D., Arias-Carrión O., Drucker-Colín R. Administration of URB597, oleoylethanolamide or palmitoylethanolamide increases waking and dopamine in rats. PLoS One 2011, 6:e20766.
64. Nestler E.J. Molecular mechanisms of drug addiction. Neuropharmacology 2004, 47:24-32.
65. Onaivi E., Leonard C., Ishiguro H., Wu Zhang P., Lin Z., Akinshola B., et al. Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol 2002, 66:307-344.
66. Orio L., Edwards S., George O., Parsons L.H., Koob G.F. A role for the endocannabinoid system in the increased motivation for cocaine in extended-access conditions. J Neurosci 2009, 29:4846-4857.
67. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego. 4th ed.
68. Piomelli D. The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 2003, 4:873-884.
69. Plaza-Zabala A., Berrendero F., Suarez J., Bermudez-Silva F.J., Fernandez-Espejo E., Serrano A., et al. Effects of the endogenous PPAR-alpha agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice. Synapse 2010, 64:379-389.
70. Ranganath C., Ritchey M. Two cortical systems for memory-guided behaviour. Nat Rev Neurosci 2012, 13:713-726.
71. Rivera P., Miguéns M., Coria S.M., Rubio L., Higuera-Matas A., Bermúdez-Silva F.J., et al. Cocaine self-administration differentially modulates the expression of endogenous cannabinoid system-related proteins in the hippocampus of Lewis vs. Fischer 344 rats. Int J Neuropsychopharmacol 2013, 16:1277-1293.
72. Rodríguez De Fonseca F., Gorriti M.A., Bilbao A., Escuredo L., García-Segura L.M., Piomelli D., et al. Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotox Res 2001, 3:23-35.
73. Serrano A., Pavón F.J., Tovar S., Casanueva F., Señarís R., Diéguez C., et al. Oleoylethanolamide: effects on hypothalamic transmitters and gut peptides regulating food intake. Neuropharmacology 2011, 60:593-601.
74. Shoaib M. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology 2008, 54:438-444.
75. Soria G., Mendizábal V., Touriño C., Robledo P., Ledent C., Parmentier M., et al. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 2005, 30:1670-1680.
76. Spijker S. Dissection of rodent brain regions. Neuroproteomics, Neuromethods 2011, vol. 57:13-26. Springer. K.W. Li (Ed.).
77. Suarez J., Bermudez-Silva F., Mackie K., Ledent C., Zimmer A., Cravatt B., et al. Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol 2008, 509:400-421.
78. Sugiura T., Kishimoto S., Oka S., Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 2006, 45:405-446.
79. Syed S.K., Bui H.H., Beavers L.S., Farb T.B., Ficorilli J., Chesterfield A.K., et al. Regulation of GPR119 receptor activity with endocannabinoid-like lipids. Am J Physiol Endocrinol Metab 2012, 303:1469-1478.
80. Thomsen M., Han D., Gu H., Caine B. Lack of cocaine self-administration in mice expressing a cocaine-insensitive dopamine transporter. J Pharmacol Exp Ther 2009, 331:204-211.
81. Tsuboi K., Sun Y.X., Okamoto Y., Araki N., Tonai T., Ueda N. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 2005, 280:11082-11092.
82. Twining R., Bolan M., Grigson P. Yoked delivery of cocaine is aversive and protects against the motivation for drug in rats. Behav Neurosci 2009, 123:913-925.
83. Ueda N., Yamamoto K., Yamamoto S., Tokunaga T., Shirakawa E., Shinkai H., et al. Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochim Biophys Acta 1995, 1254:127-134.
84. Ueda N., Yamanaka K., Terasawa Y., Yamamoto S. An acid amidase hydrolyzing anandamide as an endogenous ligand for cannabinoid receptors. FEBS Lett 1999, 454:267-270.
85. Ueda N., Liu Q., Yamanaka K. Marked activation of the N-acylphosphatidylethanolamine-hydrolyzing phosphodiesterase by divalent cations. Biochim Biophys Acta 2001, 1532:121-127.
86. Vigano D., Grazia Cascio M., Rubino T., Fezza F., Vaccani A., Di Marzo V., et al. Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology 2003, 28:1160-1167.
87. Xi Z.X., Newman A.H., Gilbert J.G., Pak A.C., Peng X.Q., Ashby C.R., et al. The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 2006, 31:1393-1405.
88. Xi Z.X., Spiller K., Pak A.C., Gilbert J., Dillon C., Li X., et al. Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats. Neuropsychopharmacology 2008, 33:1735-1745.
89. Xi Z.X., Peng X.Q., Li X., Song R., Zhang H.Y., Liu Q.R., et al. Brain cannabinoid CB[U+2082] receptors modulate cocaine's actions in mice. Nat Neurosci 2011, 14:1160-1166.